Search | IOVS | ARVO Journals

Showing 1 – 20 of 27

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)

loic Cm lhuillier; Hemal Mehta; Jagjit Gilhotra; Fred Chen; Sanjeewa Wickremasinghe; Wilson Heriot; Peter Davies; Lily Ooi; Jennifer Arnold; Rohan Merani; Mike Taylor; David O Bates; Samantha Fraser-Bell; Mark C Gillies; Mario G Fsadni; Andrew Chang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6248.

ARVO Annual Meeting Abstract June 2024

High retinal and low systemic exposure of EXN407 eye drops in humans, a new topical therapeutic for the treatment of diabetic macular edema (DME)

David O Bates; Ken McKechnie; Mike Taylor

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6240.

ARVO Annual Meeting Abstract June 2024

The splicing of VEGF-A in monocytes from people with neovascular age related macular degeneration (nAMD) and diabetic retinopathy is altered by inhibition of SRPK1 and CLK

Yizhuo Gao; Jyoti Agrawal; Jason Amartey; Tom Hawtrey; Jonathan Morris; Winfried M K Amoaku; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):829.

ARVO Annual Meeting Abstract June 2023

The influence of peripheral circulating monocytes from nAMD and DR patients on endothelial cell migration

Yizhuo Gao; David O Bates; Winfried M K Amoaku

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2947.

ARVO Annual Meeting Abstract June 2020

Choroidal and retinal expression of microfibrillar-associated protein 4 (MFAP4) in neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR)

Bartosz Pilecki; Anders Schlosser; Jing Hua; Thomas L. Andersen; Steffen Heegaard; David O Bates; Uffe Holmskov; Grith Lykke Sorensen

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1039.

ARVO Annual Meeting Abstract June 2020

MFAP4 is an Effective Therapeutic Target in a Rabbit Model of Choroidal Neovascularization (CNV)

Jing Hua; Anders Schlosser; Amy Lynch; Bartosch Pilecki; Uffe Holmskov; Andew Benest; David O Bates; Grith Lykke Sorensen

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4342.

ARVO Annual Meeting Abstract July 2019

MFAP4 – a novel potential target for treatment of vascular leakage in diabetic retinopathy

Jing Hua; Anders Schlosser; Bartosz Pilecki; Uffe Holmskov; Andew Benest; David O Bates; Claire Allen; Grith Lykke Sorensen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2726.

ARVO Annual Meeting Abstract July 2019

Designing topical VEGF-A inhibitors with high retinal bioavailability using ex vivo permeability modelling

David O Bates; Susan Liddell; Hamish Toop; Elizabeth Anne Stewart; Amy Murphy; Anthony Habgood; James Daubney; Cristina Gutierrez-Caballero; Ken McKechnie; Jonathan Morris; Jennifer Batson

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3246.

ARVO Annual Meeting Abstract July 2019

EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema, inhibits ocular neovascularisation

Jennifer Batson; Hamish Toop; Susan Liddell; James Daubney; Elizabeth Anne Stewart; Anthony Habgood; Amy Murphy; Ken McKechnie; Jonathan Morris; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):26.

ARVO Annual Meeting Abstract July 2019

Inhibition of Microfibrillar-associated Protein 4 as a Potential Therapy Targeting Choroidal Neovascularisation in Age-related Macular Degeneration

Andew Benest; Amy P Lynch; Anders Schlosser; Uffe Holmskov; Grith Lykke Sorensen; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):369.

ARVO Annual Meeting Abstract July 2018

MFAP4 supports retinal endothelial cell proliferation

Bartosz Pilecki; Anders Schlosser; David O Bates; Louise Ravn; Uffe Holmskov; Steffen Heegaard; Jakob Grauslund; Grith Lykke Sorensen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2646.

ARVO Annual Meeting Abstract June 2017

Targeting SRPK1 with novel potent and selective small molecule inhibitors inhibits choroidal neovascularisation through modulating VEGF-A alternative splicing

David O Bates; Hamish Toop; James Daubney; Elizabeth Stewart; Jonathan Morris; Jennifer Batson

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):424.

ARVO Annual Meeting Abstract June 2017

Optimisation of potent SRPK1 inhibitors through modelling of permeability properties required for trans-scleral eye drop delivery

Jennifer Batson; Hamish Toop; Elizabeth Stewart; James Daubney; Jonathan Morris; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1966.

ARVO Annual Meeting Abstract June 2017

Inhibition of Micro-Fibrillar Associated Protein 4 as a Potential Therapy Targeting Choroidal Neovascularisation in Age Related Macular Degeneration

Andew Benest; Claire Allen; Nikita Ved; Zoe Blackley; Grith Lykke Sørensen; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2311.

ARVO Annual Meeting Abstract June 2017

Hydrogen sulfide as a novel therapeutic for diabetic retinopathy

Claire Allen; Jacqueline L Whatmore; Mark E Wood; Matthew Whiteman; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4043.

ARVO Annual Meeting Abstract September 2016

Development of topically administered retinal angiogenesis inhibitors with improved ocular permeability and therapeutic exposure in rabbit eyes

Jennifer Batson; Hamish Toop; Jonathan Rowlinson; Claire Louise Allen; Gibbons Brian; Jonathan Morris; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):774.

ARVO Annual Meeting Abstract September 2016

In vivo measurement of increased vascular permeability after STZ induction of diabetes in rats by fluorescence angiography using the Micron IV

Claire Louise Allen; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4527.

Retina September 2013

Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD

PDF

Melissa V. Gammons; Oleg Fedorov; David Ivison; Chunyun Du; Tamsyn Clark; Claire Hopkins; Masatoshi Hagiwara; Andrew D. Dick; Russell Cox; Steven J. Harper; Jules C. Hancox; Stefan Knapp; David O. Bates
TAGS: angiogenesis inhibitors, choroidal neovascularization, eyedrops, proteins, rodentia, vascular endothelial growth factor a, mice, phosphotransferases, protein isoforms, lasers
Invest. Ophthalmol. Vis. Sci.. 2013; 54(9):6052-6062. https://doi.org/10.1167/iovs.13-12422

Includes: Supplemental Content

Physiology and Pharmacology August 2013

SRPK1 Inhibition Modulates VEGF Splicing to Reduce Pathological Neovascularization in a Rat Model of Retinopathy of Prematurity

PDF

Melissa V. R. Gammons; Andrew D. Dick; Steven J. Harper; David O. Bates
TAGS: vascular endothelial growth factor a, retinopathy of prematurity, neovascularization, pathologic, rna splicing
Invest. Ophthalmol. Vis. Sci.. 2013; 54(8):5797-5806. https://doi.org/10.1167/iovs.13-11634

Includes: Supplemental Content

ARVO Annual Meeting Abstract March 2012

Knockdown Of Splicing Factor Fbp21 Alters Pro - To Anti-angiogenic Vegf Protein Ratio In Primary Retinal Pigment Epithelial Cells

James G. Carter; Amanda J. Churchill; David O. Bates

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4119.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)

High retinal and low systemic exposure of EXN407 eye drops in humans, a new topical therapeutic for the treatment of diabetic macular edema (DME)

The splicing of VEGF-A in monocytes from people with neovascular age related macular degeneration (nAMD) and diabetic retinopathy is altered by inhibition of SRPK1 and CLK

The influence of peripheral circulating monocytes from nAMD and DR patients on endothelial cell migration

Choroidal and retinal expression of microfibrillar-associated protein 4 (MFAP4) in neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR)

MFAP4 is an Effective Therapeutic Target in a Rabbit Model of Choroidal Neovascularization (CNV)

MFAP4 – a novel potential target for treatment of vascular leakage in diabetic retinopathy

Designing topical VEGF-A inhibitors with high retinal bioavailability using ex vivo permeability modelling

EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema, inhibits ocular neovascularisation

Inhibition of Microfibrillar-associated Protein 4 as a Potential Therapy Targeting Choroidal Neovascularisation in Age-related Macular Degeneration

MFAP4 supports retinal endothelial cell proliferation

Targeting SRPK1 with novel potent and selective small molecule inhibitors inhibits choroidal neovascularisation through modulating VEGF-A alternative splicing

Optimisation of potent SRPK1 inhibitors through modelling of permeability properties required for trans-scleral eye drop delivery

Inhibition of Micro-Fibrillar Associated Protein 4 as a Potential Therapy Targeting Choroidal Neovascularisation in Age Related Macular Degeneration

Hydrogen sulfide as a novel therapeutic for diabetic retinopathy

Development of topically administered retinal angiogenesis inhibitors with improved ocular permeability and therapeutic exposure in rabbit eyes

In vivo measurement of increased vascular permeability after STZ induction of diabetes in rats by fluorescence angiography using the Micron IV

Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD

SRPK1 Inhibition Modulates VEGF Splicing to Reduce Pathological Neovascularization in a Rat Model of Retinopathy of Prematurity

Knockdown Of Splicing Factor Fbp21 Alters Pro - To Anti-angiogenic Vegf Protein Ratio In Primary Retinal Pigment Epithelial Cells

To View More...

You must be signed into an individual account to use this feature.